铁死亡及其细胞游离亚铁原卟啉在肿瘤发生中的作用
The Role of Ferroptosis and Its Cell Free Ferrous Protoporphyrin in Tumorigenesis
摘要: 铁死亡(ferroptosis)是一种铁依赖性的调节性细胞死亡形式,由过度的脂质过氧化所引起,它与各种类型肿瘤的发生和治疗反应密切相关。然而,铁死亡性损伤(ferroptotic)可在恶性肿瘤微环境中触发炎症相关的免疫抑制,因而有利于肿瘤的生长。尽管一些研究已经发现癌症相关基因(例如RAS和TP53)的突变、与应激反应通路(stress response pathways) (如NFE2L2信号、自噬和缺氧)有关的蛋白的基因突变与上皮间质转化以及可激活铁死亡的治疗反应之间存在重要的相关性。目前铁死亡对肿瘤生物学的影响程度尚不清楚,尤其是消化道肿瘤中的铁死亡的调节机制、信号通路及其可检测的生物标志物;因此,寻找有助于检测和追踪铁死亡的生物标记物目前成为研究的热点。有研究认为,细胞游离亚铁原卟啉(cell free ferrous protoporphyrin, FH)是含亚铁原卟啉蛋白的分解产物,具有强氧化作用,导致细胞自身调节功能紊乱,与细胞癌变程度直接密切相关,目前已应用于宫颈癌、结直肠癌、尿路上皮癌等方面的检测,成为恶性肿瘤发生过程中产生的因果性生物标志因子。现就铁死亡机制及信号通路及其组织标志物细胞游离亚铁原卟啉FH在肿瘤发生中的作用作一综述,为肿瘤的诊治提供新的思路和方法。
Abstract: Ferroptosis is a form of iron-dependent regulatory cell death caused by excessive lipid peroxidation, which is closely related to the occurrence and treatment of various types of tumors. However, fer-roptotic injury can trigger inflammation-related immunosuppression in the microenvironment of malignant tumors, which is conducive to tumor growth. Although some studies have found that there is an important correlation between mutations in cancer-related genes (such as RAS and TP53), gene mutations in proteins related to stress response pathways (such as NFE2L2 signaling, autophagy, and hypoxia) and epithelial-mesenchymal transition and therapeutic responses that ac-tivate ferroptosis. At present, the effect of ferroptosis on tumor biology is not clear, especially the regulation mechanism, signaling pathway and detectable biomarkers of ferroptosis in digestive tract tumors; therefore, the search for biomarkers to help detect and track ferroptosis is currently a hot research topic. Studies have shown that cell free ferrous protoporphyrin (FH) is a decomposition product of ferrous protoporphyrin protein, which has a strong oxidation effect, leading to the disor-der of cell self-regulation function, which is directly related to the degree of cell carcinogenesis. It has been applied to the detection of cervical cancer, colorectal cancer, urothelial carcinoma and other aspects, and has become a causal biomarker factor in the process of malignant tumor. This ar-ticle reviews the mechanism and signaling pathway of ferroptosis and the role of its tissue marker cell free ferrous protoporphyrin FH in tumorigenesis, and provides new ideas and methods for the diagnosis and treatment of tumors.
文章引用:朱士法, 孔令斌. 铁死亡及其细胞游离亚铁原卟啉在肿瘤发生中的作用[J]. 临床医学进展, 2022, 12(11): 10184-10190. https://doi.org/10.12677/ACM.2022.12111468

参考文献

[1] Skoupilová, H., Michalová, E. and Hrstka, R. (2018) Ferroptosis as a New Type of Cell Death and Its Role in Cancer Treatment. Klinická onkologie: Casopis Ceské a Slovenské onkologické spolecnosti, 31, 21-26. [Google Scholar] [CrossRef
[2] Orino, K. (2013) Functional Binding Analysis of Human Fibrinogen as an Iron- and Heme-Binding Protein. Biometals: An International Journal on the Role of Metal Ions in Biology, Bio-chemistry, and Medicine, 26, 789-794. [Google Scholar] [CrossRef] [PubMed]
[3] 朱智宇, 许国诚, 林晔, 魏良宝, 雷辉, 袁阁林. 直肠上皮细胞稳定性FH检测对直肠癌筛查诊治的临床研究[J]. 中外医疗, 2019, 38(6): 189-191.
[4] 王昕昕, 索冰, 李超, 等. 直肠黏膜渗液FH检测在非手术直肠癌局部疗效评价中的临床意义[J]. 中华普外科手术学杂志(电子版), 2019, 13(3): 270-272.
[5] Lei, G., Zhuang, L. and Gan, B. (2022) Targeting Ferroptosis as a Vulnerability in Cancer. Nature Reviews. Cancer, 22, 381-396. [Google Scholar] [CrossRef] [PubMed]
[6] Xie, Y., Hou, W., Song, X., et al. (2016) Ferroptosis: Process and Function. Cell Death and Differentiation, 23, 369-379. [Google Scholar] [CrossRef] [PubMed]
[7] Valashedi, M.R., Nikoo, A., Najafi-Ghalehlou, N., et al. (2022) Phar-macological Targeting of Ferroptosis in Cancer Treatment. Current Cancer Drug Targets, 22, 108-125. [Google Scholar] [CrossRef] [PubMed]
[8] Mbah, N.E. and Lyssiotis, C.A. (2022) Metabolic Regulation of Ferroptosis in the Tumor Microenvironment. The Journal of Biological Chemistry, 298, Article ID: 101617. [Google Scholar] [CrossRef] [PubMed]
[9] Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M. and Stites, E.C. (2021) Cancer Gene Mutation Frequencies for the U.S. Population. Nature Communications, 12, Article No. 5961.
[10] Dolgin, E. (2017) The Most Popular Genes in the Human Genome. Nature, 551, 427-431. [Google Scholar] [CrossRef] [PubMed]
[11] Hernández Borrero, L.J. and El-Deiry, W.S. (2021) Tumor Sup-pressor p53: Biology, Signaling Pathways, and Therapeutic Targeting. Biochimica et Biophysica Acta. Reviews on Cancer, 1876, Article ID: 188556. [Google Scholar] [CrossRef] [PubMed]
[12] Harris, S.L. and Levine, A.J. (2005) The p53 Pathway: Positive and Negative Feedback Loops. Oncogene, 24, 2899- 2908. [Google Scholar] [CrossRef] [PubMed]
[13] Chen, J. (2016) The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harbor Perspectives in Medicine, 6, a026104. [Google Scholar] [CrossRef] [PubMed]
[14] Xue, W., Zender, L., Miething, C., et al. (2007) Senescence and Tumour Clearance Is Triggered by p53 Restoration in Murine Liver Carcino-mas. Nature, 445, 656-660. [Google Scholar] [CrossRef] [PubMed]
[15] Chu, B., Kon, N., Chen, D., et al. (2019) ALOX12 Is Required for p53-Mediated Tumour Suppression through a Distinct Ferroptosis Pathway. Nature Cell Biol-ogy, 21, 579-591. [Google Scholar] [CrossRef] [PubMed]
[16] Lu, J., Xu, F. and Lu, H. (2020) LncRNA PVT1 Regulates Ferroptosis through miR-214-Mediated TFR1 and p53. Life Sciences, 260, Article ID: 118305. [Google Scholar] [CrossRef] [PubMed]
[17] Xiong, X., Yuan, J., Zhang, N., Zheng, Y., Liu, J. and Yang, M. (2020) Silencing of lncRNA PVT1 by miR-214 Inhibits the Oncogenic GDF15 Signaling and Suppresses Hepatocar-cinogenesis. Biochemical and Biophysical Research Communications, 521, 478-484. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, Z., Guo, M., Shen, M., et al. (2020) The BRD7-P53-SLC25A28 Axis Regulates Ferroptosis in Hepatic Stellate Cells. Redox Biology, 36, Article ID: 101619. [Google Scholar] [CrossRef] [PubMed]
[19] Xie, Y., Zhu, S., Song, X., et al. (2017) The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Reports, 20, 1692-1704. [Google Scholar] [CrossRef] [PubMed]
[20] Lossaint, G., Horvat, A., Gire, V., et al. (2022) Reciprocal Regu-lation of p21 and Chk1 Controls the Cyclin D1-RB Pathway to Mediate Senescence Onset after G2 Arrest. Journal of Cell Science, 135, jcs259114. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, D., Chu, B., Yang, X., et al. (2021) iPLA2β-Mediated Lipid Detoxi-fication Controls p53-Driven Ferroptosis Independent of GPX4. Nature Communications, 12, Article No. 3644. [Google Scholar] [CrossRef] [PubMed]
[22] Lane, D. and Levine, A. (2010) p53 Research: The Past Thirty Years and the Next Thirty Years. Cold Spring Harbor Perspectives in Biology, 2, a000893. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, G.L., Jiang, B.H., Rue, E.A. and Semenza, G.L. (1995) Hypoxia-Inducible Factor 1 Is a Basic-helix-loop-helix- PAS Heterodimer Regulated by Cellular O2 Tension. Proceed-ings of the National Academy of Sciences of the United States of America, 92, 5510-5514. [Google Scholar] [CrossRef] [PubMed]
[24] Panieri, E. and Santoro, M.M. (2016) ROS Homeostasis and Metab-olism: A Dangerous Liason in Cancer Cells. Cell Death & Disease, 7, e2253. [Google Scholar] [CrossRef] [PubMed]
[25] Srinivas, U.S., Tan, B., Vellayappan, B.A. and Jeyasekharan, A.D. (2019) ROS and the DNA Damage Response in Cancer. Redox Biology, 25, Article ID: 101084. [Google Scholar] [CrossRef] [PubMed]
[26] Xue, X., Ramakrishnan, S.K. and Shah, Y.M. (2014) Activation of HIF-1α Does Not Increase Intestinal Tumorigenesis. American Journal of Physiology. Gastrointestinal and Liver Physiology, 307, G187-G195. [Google Scholar] [CrossRef] [PubMed]
[27] Shay, J.E., Imtiyaz, H.Z., Sivanand, S., et al. (2014) Inhibition of Hypoxia-Inducible Factors Limits Tumor Progression in a Mouse Model of Colorectal Cancer. Carcinogenesis, 35, 1067-1077. [Google Scholar] [CrossRef] [PubMed]
[28] Xue, X., Ramakrishnan, S.K., Weisz, K., et al. (2016) Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis. Cell Metabo-lism, 24, 447-461. [Google Scholar] [CrossRef] [PubMed]
[29] Triner, D. and Shah, Y.M. (2016) Hypoxia-Inducible Factors: A Central Link between Inflammation and Cancer. The Journal of Clinical Investigation, 126, 3689-3698. [Google Scholar] [CrossRef
[30] Suzuki, R.N., Newman, S.P., Purohit, A., Leese, M.P., Potter, B.V. and Reed, M.J. (2003) Growth Inhibition of Multi-Drug-Resistant Breast Cancer Cells by 2-Methoxyoestradiol-bis-sulphamate and 2-Ethyloestradiol-bis-sulphamate. The Journal of Steroid Biochemistry and Molecular Biology, 84, 269-278. [Google Scholar] [CrossRef
[31] Lee, K. and Kim, H.M. (2011) A Novel Approach to Cancer Therapy Using PX-478 as a HIF-1α Inhibitor. Archives of Pharmacal Research, 34, 1583-1585. [Google Scholar] [CrossRef] [PubMed]
[32] Palayoor, S.T., Mitchell, J.B., Cerna, D., Degraff, W., John-Aryankalayil, M. and Coleman, C.N. (2008) PX-478, an Inhibitor of Hypoxia-Inducible Factor-1alpha, Enhances Radiosensitivity of Prostate Carcinoma Cells. International Journal of Cancer, 123, 2430-2437. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, W., Hill, H., Christie, A., et al. (2016) Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Nature, 539, 112-117. [Google Scholar] [CrossRef] [PubMed]
[34] Cho, H., Du, X., Rizzi, J.P., et al. (2016) On-Target Efficacy of a HIF-2α Antagonist in Preclinical Kidney Cancer Models. Nature, 539, 107-111. [Google Scholar] [CrossRef] [PubMed]
[35] Zhang, Y., Marcillat, O., Giulivi, C., Ernster, L. and Davies, K.J. (1990) The Oxidative Inactivation of Mitochondrial Electron Transport Chain Components and ATPase. The Journal of Biological Chemistry, 265, 16330-16336. [Google Scholar] [CrossRef
[36] Cadenas, E. and Davies, K.J. (2000) Mitochondrial Free Radical Generation, Oxidative Stress, and Aging. Free Radical Biology & Medicine, 29, 222-230. [Google Scholar] [CrossRef
[37] Jakubczyk, K., Dec, K., Kałduńska, J., Kawczuga, D., Kochman, J. and Janda, K. (2020) Reactive Oxygen Species—Sources, Functions, Oxidative Damage. Pol-skimerkuriuszlekarski: Organ Polskiego Towarzystwa Lekarskiego, 48, 124-127.
[38] Chiabrando, D., Vinchi, F., Fio-rito, V., Mercurio, S. and Tolosano, E. (2014) Heme in Pathophysiology: A Matter of Scavenging, Metabolism and Traf-ficking across Cell Membranes. Frontiers in Pharmacology, 5, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[39] Li, S., Chen, Z., Chen, R., et al. (2022) Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC. Cancer Management and Research, 14, 2291-2297. [Google Scholar] [CrossRef
[40] Kawai, K., Hirayama, T., Imai, H., et al. (2022) Molecular Imaging of Labile Heme in Living Cells Using a Small Molecule Fluorescent Probe. Journal of the American Chemical Society, 144, 3793-3803. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, T., Ashrafi, A., Modareszadeh, P., et al. (2021) An Analysis of the Multifaceted Roles of Heme in the Pathogenesis of Cancer and Related Diseases. Cancers, 13, Article No. 4142. [Google Scholar] [CrossRef] [PubMed]